Information Provided By: 
Fly News Breaks for September 26, 2016
JAZZ
Sep 26, 2016 | 06:46 EDT
JPMorgan analyst Jessica Fye believes the recent selloff in shares of Jazz Pharmaceuticals creates an attractive entry point for investors with a greater than three month time horizon. The analyst sees a "strong probability of success" for the JZP-110 Phase III data in early 2017 and believes the company's acquisition of Celator should help reduce the reliance on Xyrem, particularly post-2020. Fye keeps an Overweight rating on Jazz with a $205 price target.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
